Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Cyclacel Pharmaceuticals (CYCC)
NASDAQ:CYCC
RESEARCH TOOLSreports
Holding CYCC?
Track your performance easily
CYCC Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$0.32 - $6.00
Previous Close$0.35
Volume170.49K
Average Volume (3M)1.44M
Market Cap
$2.26M
Enterprise Value-$798.45K
Total Cash (Recent Filing)$2.98M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta0.66
Next Earnings
Apr 01, 2025EPS Estimate
-$0.29Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-11.21
Shares Outstanding6,287,205
10 Day Avg. Volume2,483,081
30 Day Avg. Volume1,435,056
Standard Deviation0.27
R-Squared0.01
Alpha-0.05
Financial Highlights & Ratios
Price to Book (P/B)-2.48
Price to Sales (P/S)31.74
Price to Cash Flow (P/CF)-0.20
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue-10.79
Enterprise Value/Gross Profit-1.90
Enterprise Value/Ebitda0.05
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusHold
Number of Analyst Covering1
Cyclacel Pharmaceuticals News
PremiumCompany Announcements
Cyclacel Pharmaceuticals Reports Q3 2024 Financial Results
Ownership Overview
1.86% Insiders
0.22% Mutual Funds
2.31% Other Institutional Investors
95.51% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
CYCC FAQ
What was Cyclacel Pharmaceuticals’s price range in the past 12 months?
Cyclacel Pharmaceuticals lowest stock price was $0.32 and its highest was $6.00 in the past 12 months.
What is Cyclacel Pharmaceuticals’s market cap?
Currently, no data Available
When is Cyclacel Pharmaceuticals’s upcoming earnings report date?
Cyclacel Pharmaceuticals’s upcoming earnings report date is Apr 01, 2025 which is in 130 days.
How were Cyclacel Pharmaceuticals’s earnings last quarter?
Cyclacel Pharmaceuticals released its earnings results on Nov 12, 2024. The company reported -$0.18 earnings per share for the quarter, beating the consensus estimate of -$0.54 by $0.36.
Is Cyclacel Pharmaceuticals overvalued?
According to Wall Street analysts Cyclacel Pharmaceuticals’s price is currently Overvalued.
Does Cyclacel Pharmaceuticals pay dividends?
Cyclacel Pharmaceuticals does not currently pay dividends.
What is Cyclacel Pharmaceuticals’s EPS estimate?
Cyclacel Pharmaceuticals’s EPS estimate is -$0.29.
How many shares outstanding does Cyclacel Pharmaceuticals have?
Cyclacel Pharmaceuticals has 6,287,205 shares outstanding.
What happened to Cyclacel Pharmaceuticals’s price movement after its last earnings report?
Cyclacel Pharmaceuticals reported an EPS of -$0.18 in its last earnings report, beating expectations of -$0.54. Following the earnings report the stock price went up 9.756%.
Which hedge fund is a major shareholder of Cyclacel Pharmaceuticals?
Currently, no hedge funds are holding shares in CYCC
---
Cyclacel Pharmaceuticals Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Hold
Average Price Target:
― (―)
― (―)
Blogger Sentiment
Bullish
CYCC Sentiment 100%
Sector Average 72%
Sector Average 72%
Crowd Wisdom
Very Positive
Last 7 Days ▲ 1.3%
Last 30 Days ▲ 26.5%
Last 30 Days ▲ 26.5%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-91.46%
12-Months-Change
Fundamentals
Return on Equity
-807.39%
Trailing 12-Months
Asset Growth
-56.94%
Trailing 12-Months
Company Description
Cyclacel Pharmaceuticals
Cyclacel Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. It uses cell cycle, transcriptional regulation and DNA damage response biology to develop innovative, targeted medicines for cancer and other proliferative diseases. The company builds a diversified biopharmaceutical business, which is focused in hematology and oncology based on a pipeline of novel drug candidates. Its products include CYC065, seliciclib, and sapacitabine. The company was founded by Ronald J. Berenson, David Philip Lane, and David Glover on August 13, 1996 and is headquartered in Berkeley Heights, NJ.
---
CYCC Earnings Call
Q2 2024
0:00 / 0:00
---
CYCC Stock 12 Month Forecast
Average Price Target
―Technical Analysis
TRACON Pharmaceuticals
―
Oncternal Therapeutics
―
Adaptimmune Therapeutics
―
Kazia Therapeutics
―
---